BioMarin Pharma (BMRN) reported third quarter earnings of $6.6 million or 6 cents per share on a GAAP basis, higher than $0.8 million or 1 cent per share last year. The company's adjusted earnings were higher at $15.5 million or 13 cents per share compared with $8.2 million or 8 cents per share in the year-ago period.
On average, 19 analysts polled by Thomson Reuters expected earnings of 1 cent per share. Analysts' estimates typically exclude one-time items.
Revenues rose to $80.81 million from the year-ago's $72.65 million. Analysts, on average, expected revenues of $81.92 million.
For the full year, the company guided revenues to $313 million to $327 million, an upward revision from its earlier estimate of $311 million to $336 million. The company also lifted its non-GAAP earnings guidance to $39.8 million to $43.8 million from its earlier estimate of $35.4 million to $41.4 million.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.